{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:42:49Z","timestamp":1793835769851,"version":"4.6.1"},"reference-count":328,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41568-024-00785-5","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T04:49:43Z","timestamp":1738126183000},"page":"249-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["Cross-priming in cancer immunology and immunotherapy"],"prefix":"10.1038","volume":"25","author":[{"given":"Carlos","family":"Luri-Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5565-8561","authenticated-orcid":false,"given":"Stefanie K.","family":"Wculek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"de Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Lopez-Janeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Rodr\u00edguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aggelakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-1865","authenticated-orcid":false,"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"785_CR1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211519","volume":"219","author":"R Wu","year":"2022","unstructured":"Wu, R. & Murphy, K. M. DCs at the center of help: origins and evolution of the three-cell-type hypothesis. J. Exp. Med. 219, e20211519 (2022).","journal-title":"J. Exp. Med."},{"key":"785_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.4049\/jimmunol.1090065","volume":"185","author":"FR Carbone","year":"2010","unstructured":"Carbone, F. R. & Heath, W. R. Cross-priming: its beginnings. J. Immunol. 185, 1353\u20131354 (2010).","journal-title":"J. Immunol."},{"key":"785_CR3","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR Sanchez-Paulete","year":"2017","unstructured":"Sanchez-Paulete, A. R. et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann. Oncol. 28, xii44\u2013xii55 (2017).","journal-title":"Ann. Oncol."},{"key":"785_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557\u2013569 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"785_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/ni0406-363","volume":"7","author":"MJ Bevan","year":"2006","unstructured":"Bevan, M. J. Cross-priming. Nat. Immunol. 7, 363\u2013365 (2006).","journal-title":"Nat. Immunol."},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1084\/jem.143.5.1283","volume":"143","author":"MJ Bevan","year":"1976","unstructured":"Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143, 1283\u20131288 (1976). This seminal experimental work by Michael Bevan and colleagues reveals the existence of cross-priming, demonstrating that endogenous professional APCs ought to be able to process and present antigens from other cells to prime cytotoxic T cell responses.","journal-title":"J. Exp. Med."},{"key":"785_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1084\/jem.171.2.377","volume":"171","author":"FR Carbone","year":"1990","unstructured":"Carbone, F. R. & Bevan, M. J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171, 377\u2013387 (1990).","journal-title":"J. Exp. Med."},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JM den Haan","year":"2000","unstructured":"den Haan, J. M., Lehar, S. M. & Bevan, M. J. CD8+ but not CD8\u2212 dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685\u20131696 (2000).","journal-title":"J. Exp. Med."},{"key":"785_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","volume":"137","author":"RM Steinman","year":"1973","unstructured":"Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142\u20131162 (1973).","journal-title":"J. Exp. Med."},{"key":"785_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman, R. M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1\u201322 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"785_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41577-020-00413-x","volume":"21","author":"DA Anderson 3rd","year":"2021","unstructured":"Anderson, D. A. 3rd, Dutertre, C. A., Ginhoux, F. & Murphy, K. M. Genetic models of human and mouse dendritic cell development and function. Nat. Rev. Immunol. 21, 101\u2013115 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"785_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.mcb.2023.05.008","volume":"183","author":"G Schreibelt","year":"2024","unstructured":"Schreibelt, G. et al. Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy. Methods Cell Biol. 183, 33\u201350 (2024).","journal-title":"Methods Cell Biol."},{"key":"785_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002054","volume":"9","author":"FJ Cueto","year":"2021","unstructured":"Cueto, F. J. et al. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J. Immunother. Cancer 9, e002054 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2013.07.014","volume":"154","author":"BU Schraml","year":"2013","unstructured":"Schraml, B. U. et al. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 154, 843\u2013858 (2013).","journal-title":"Cell"},{"key":"785_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.20091627","volume":"207","author":"BT Edelson","year":"2010","unstructured":"Edelson, B. T. et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J. Exp. Med. 207, 823\u2013836 (2010).","journal-title":"J. Exp. Med."},{"key":"785_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I., Adan-Barrientos, I., Galan, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"785_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ni.3197","volume":"16","author":"GE Grajales-Reyes","year":"2015","unstructured":"Grajales-Reyes, G. E. et al. Batf3 maintains autoactivation of Irf8 for commitment of a CD8alpha+ conventional DC clonogenic progenitor. Nat. Immunol. 16, 708\u2013717 (2015).","journal-title":"Nat. Immunol."},{"key":"785_CR18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41590-019-0449-3","volume":"20","author":"P Bagadia","year":"2019","unstructured":"Bagadia, P. et al. An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development. Nat. Immunol. 20, 1174\u20131185 (2019).","journal-title":"Nat. Immunol."},{"key":"785_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris, S. T. et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature 584, 624\u2013629 (2020). This study highlights the essential role of cDC1 licensing via the CD40\u2013CD40L interaction with CD4\u00b1 T cells and shows the relevance of this phenomenon for cross-priming CD8\u00b1 T cells for effective tumour rejection.","journal-title":"Nature"},{"key":"785_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.immuni.2015.04.017","volume":"42","author":"R Tussiwand","year":"2015","unstructured":"Tussiwand, R. et al. Klf4 expression in conventional dendritic cells is required for T helper 2 cell responses. Immunity 42, 916\u2013928 (2015).","journal-title":"Immunity"},{"key":"785_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","volume":"45","author":"M Guilliams","year":"2016","unstructured":"Guilliams, M. et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45, 669\u2013684 (2016).","journal-title":"Immunity"},{"key":"785_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell 177, 556\u2013571.e516 (2019).","journal-title":"Cell"},{"key":"785_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71\u201379 (2016). This study demonstrates that BATF3-dependent cDC1s are required for the efficacy of immunotherapy with PD1 and CD137 monoclonal antibodies.","journal-title":"Cancer Discov."},{"key":"785_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016). This study shows that BATF3-dependent cDC1s are crucial for the success of immunotherapy using the immune checkpoint inhibitor anti-PDL1.","journal-title":"Immunity"},{"key":"785_CR25","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-22-1046","volume":"82","author":"A Teijeira","year":"2022","unstructured":"Teijeira, A. et al. Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy. Cancer Res. 82, 4373\u20134385 (2022). First evidence that upon depletion of cDC1s in XCR1-DTR mice, the efficacy of various immunotherapy approaches (immune checkpoint inhibitors, CD137 agonists and adoptive T cell therapy) are reduced. Furthermore, depletion of cDC1s gives rise to immune-desert TMEs.","journal-title":"Cancer Res."},{"key":"785_CR26","doi-asserted-by":"publisher","first-page":"101711","DOI":"10.1016\/j.smim.2023.101711","volume":"66","author":"RA Ohara","year":"2023","unstructured":"Ohara, R. A. & Murphy, K. M. The evolving biology of cross-presentation. Semin. Immunol. 66, 101711 (2023).","journal-title":"Semin. Immunol."},{"key":"785_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo, M. et al. Dendritic cells revisited. Annu. Rev. Immunol. 39, 131\u2013166 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"785_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2019.12.005","volume":"64","author":"JD Colbert","year":"2020","unstructured":"Colbert, J. D., Cruz, F. M. & Rock, K. L. Cross-presentation of exogenous antigens on MHC I molecules. Curr. Opin. Immunol. 64, 1\u20138 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"785_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2023.08.002","volume":"159","author":"JM Blander","year":"2023","unstructured":"Blander, J. M., Yee Mon, K. J., Jha, A. & Roycroft, D. The show and tell of cross-presentation. Adv. Immunol. 159, 33\u2013114 (2023).","journal-title":"Adv. Immunol."},{"key":"785_CR30","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"785_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/imcb.12186","volume":"96","author":"SJ Cook","year":"2018","unstructured":"Cook, S. J. et al. Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2. Immunol. Cell Biol. 96, 1131\u20131139 (2018).","journal-title":"Immunol. Cell Biol."},{"key":"785_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta, M. et al. Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 9, 1124\u20131141 (2019).","journal-title":"Cancer Discov."},{"key":"785_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015). This study reveals that \u03b2-catenin activation in tumour cells reduces the recruitment of cDC1s to tumours and thereby hampers tumour immunity.","journal-title":"Nature"},{"key":"785_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj, D. et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35, 885\u2013900.e810 (2019).","journal-title":"Cancer Cell"},{"key":"785_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington, N. D., Cursons, J. & Rautela, J. The cancer\u2013natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437\u2013454 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"785_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037.e1014 (2018). This study demonstrates that NK cell-derived chemokines CCL5 and XCL1 attract cDC1s to tumours and that this activity may be hampered by PGE2.","journal-title":"Cell"},{"key":"785_CR37","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry, K. C. et al. A natural killer\u2013dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178\u20131191 (2018). This study demonstrates that FLT3L derived from intratumoural NK cells dictates the abundance of cDC1s within the TME, and that the cDC1 and NK cell signatures correlate with patient responsiveness to anti-PD1 immunotherapy and improved overall survival.","journal-title":"Nat. Med."},{"key":"785_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cellimm.2003.09.008","volume":"225","author":"A Yada","year":"2003","unstructured":"Yada, A. et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI\/III-mediated immune complex uptake. Cell Immunol. 225, 21\u201332 (2003).","journal-title":"Cell Immunol."},{"key":"785_CR39","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1158\/1078-0432.CCR-04-1702","volume":"11","author":"T Iwata","year":"2005","unstructured":"Iwata, T. et al. Frequent immune responses to a cancer\/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. 11, 3949\u20133957 (2005).","journal-title":"Clin. Cancer Res."},{"key":"785_CR40","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.20020338","volume":"195","author":"AM Kalergis","year":"2002","unstructured":"Kalergis, A. M. & Ravetch, J. V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195, 1653\u20131659 (2002).","journal-title":"J. Exp. Med."},{"key":"785_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4049\/jimmunol.1103703","volume":"189","author":"N van Montfoort","year":"2012","unstructured":"van Montfoort, N. et al. Fcgamma receptor IIb strongly regulates Fcgamma receptor-facilitated T cell activation by dendritic cells. J. Immunol. 189, 92\u2013101 (2012).","journal-title":"J. Immunol."},{"key":"785_CR42","doi-asserted-by":"publisher","first-page":"8440","DOI":"10.4049\/jimmunol.177.12.8440","volume":"177","author":"Y Liu","year":"2006","unstructured":"Liu, Y. et al. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. J. Immunol. 177, 8440\u20138447 (2006).","journal-title":"J. Immunol."},{"key":"785_CR43","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1073\/pnas.0500014102","volume":"102","author":"KM Dhodapkar","year":"2005","unstructured":"Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102, 2910\u20132915 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR44","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.4049\/jimmunol.1602169","volume":"198","author":"NI Ho","year":"2017","unstructured":"Ho, N. I. et al. C1q-dependent dendritic cell cross-presentation of in vivo-formed antigen-antibody complexes. J. Immunol. 198, 4235\u20134243 (2017).","journal-title":"J. Immunol."},{"key":"785_CR45","first-page":"229","volume":"65","author":"J Arvieux","year":"1988","unstructured":"Arvieux, J., Yssel, H. & Colomb, M. G. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 65, 229\u2013235 (1988).","journal-title":"Immunology"},{"key":"785_CR46","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1073\/pnas.1316877111","volume":"111","author":"L Baudino","year":"2014","unstructured":"Baudino, L. et al. C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens. Proc. Natl Acad. Sci. USA 111, 1503\u20131508 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR47","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.4049\/jimmunol.179.9.5793","volume":"179","author":"PN Lalli","year":"2007","unstructured":"Lalli, P. N., Strainic, M. G., Lin, F., Medof, M. E. & Heeger, P. S. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J. Immunol. 179, 5793\u20135802 (2007).","journal-title":"J. Immunol."},{"key":"785_CR48","doi-asserted-by":"publisher","first-page":"108995","DOI":"10.1016\/j.celrep.2021.108995","volume":"35","author":"SH Kim","year":"2021","unstructured":"Kim, S. H., Cho, B. H., Kim, K. S. & Jang, Y. S. Complement C5a promotes antigen cross-presentation by Peyer\u2019s patch monocyte-derived dendritic cells and drives a protective CD8+ T cell response. Cell Rep. 35, 108995 (2021).","journal-title":"Cell Rep."},{"key":"785_CR49","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/ni.2670","volume":"14","author":"ZG Ramirez-Ortiz","year":"2013","unstructured":"Ramirez-Ortiz, Z. G. et al. The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity. Nat. Immunol. 14, 917\u2013926 (2013).","journal-title":"Nat. Immunol."},{"key":"785_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1074-7613(02)00388-6","volume":"17","author":"Y Delneste","year":"2002","unstructured":"Delneste, Y. et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17, 353\u2013362 (2002).","journal-title":"Immunity"},{"key":"785_CR51","doi-asserted-by":"publisher","first-page":"101726","DOI":"10.1016\/j.smim.2023.101726","volume":"66","author":"CM Henry","year":"2023","unstructured":"Henry, C. M., Castellanos, C. A. & Reis e Sousa, C. DNGR-1-mediated cross-presentation of dead cell-associated antigens. Semin. Immunol. 66, 101726 (2023).","journal-title":"Semin. Immunol."},{"key":"785_CR52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature07750","volume":"458","author":"D Sancho","year":"2009","unstructured":"Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458, 899\u2013903 (2009). Identification of CLEC9A as the most relevant receptor on cDC1s mediating internalization for cross-presentation of necrotic cell debris.","journal-title":"Nature"},{"key":"785_CR53","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1016\/j.cell.2021.05.021","volume":"184","author":"E Giampazolias","year":"2021","unstructured":"Giampazolias, E. et al. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell 184, 4016\u20134031 e4022 (2021).","journal-title":"Cell"},{"key":"785_CR54","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1073\/pnas.1505924112","volume":"112","author":"L Cao","year":"2015","unstructured":"Cao, L., Shi, X., Chang, H., Zhang, Q. & He, Y. pH-Dependent recognition of apoptotic and necrotic cells by the human dendritic cell receptor DEC205. Proc. Natl Acad. Sci. USA 112, 7237\u20137242 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR55","doi-asserted-by":"publisher","first-page":"13438","DOI":"10.1073\/pnas.1609331113","volume":"113","author":"L Cao","year":"2016","unstructured":"Cao, L., Chang, H., Shi, X., Peng, C. & He, Y. Keratin mediates the recognition of apoptotic and necrotic cells through dendritic cell receptor DEC205\/CD205. Proc. Natl Acad. Sci. USA 113, 13438\u201313443 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR56","doi-asserted-by":"publisher","first-page":"16270","DOI":"10.1073\/pnas.1208796109","volume":"109","author":"MH Lahoud","year":"2012","unstructured":"Lahoud, M. H. et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl Acad. Sci. USA 109, 16270\u201316275 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR57","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.4049\/jimmunol.176.11.6770","volume":"176","author":"S Burgdorf","year":"2006","unstructured":"Burgdorf, S., Lukacs-Kornek, V. & Kurts, C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J. Immunol. 176, 6770\u20136776 (2006).","journal-title":"J. Immunol."},{"key":"785_CR58","doi-asserted-by":"publisher","first-page":"3845247","DOI":"10.1155\/2016\/3845247","volume":"2016","author":"T Garcia-Aguilar","year":"2016","unstructured":"Garcia-Aguilar, T., Espinosa-Cueto, P., Magallanes-Puebla, A. & Mancilla, R. The mannose receptor is involved in the phagocytosis of mycobacteria-induced apoptotic cells. J. Immunol. Res. 2016, 3845247 (2016).","journal-title":"J. Immunol. Res."},{"key":"785_CR59","doi-asserted-by":"publisher","first-page":"9933","DOI":"10.1073\/pnas.1102397108","volume":"108","author":"M Zehner","year":"2011","unstructured":"Zehner, M. et al. Mannose receptor polyubiquitination regulates endosomal recruitment of p97 and cytosolic antigen translocation for cross-presentation. Proc. Natl Acad. Sci. USA 108, 9933\u20139938 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.molimm.2012.10.031","volume":"55","author":"Y van Kooyk","year":"2013","unstructured":"van Kooyk, Y., Unger, W. W., Fehres, C. M., Kalay, H. & Garcia-Vallejo, J. J. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol. Immunol. 55, 143\u2013145 (2013).","journal-title":"Mol. Immunol."},{"key":"785_CR61","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1182\/blood-2006-10-051375","volume":"111","author":"MM Weck","year":"2008","unstructured":"Weck, M. M. et al. hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood 111, 4264\u20134272 (2008).","journal-title":"Blood"},{"key":"785_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22535-z","volume":"12","author":"N Caronni","year":"2021","unstructured":"Caronni, N. et al. TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses. Nat. Commun. 12, 2237 (2021).","journal-title":"Nat. Commun."},{"key":"785_CR63","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","volume":"113","author":"M Nakayama","year":"2009","unstructured":"Nakayama, M. et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113, 3821\u20133830 (2009).","journal-title":"Blood"},{"key":"785_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon, K. O. et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 595, 101\u2013106 (2021).","journal-title":"Nature"},{"key":"785_CR65","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"785_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","volume":"13","author":"S Gallucci","year":"2001","unstructured":"Gallucci, S. & Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114\u2013119 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"785_CR67","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991\u20131045 (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"785_CR68","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.4049\/jimmunol.1002845","volume":"186","author":"I Jelinek","year":"2011","unstructured":"Jelinek, I. et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 186, 2422\u20132429 (2011).","journal-title":"J. Immunol."},{"key":"785_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1631\/jzus.B2000808","volume":"22","author":"Y Chen","year":"2021","unstructured":"Chen, Y., Lin, J., Zhao, Y., Ma, X. & Yi, H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J. Zhejiang Univ. Sci. B 22, 609\u2013632 (2021).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"785_CR70","doi-asserted-by":"publisher","first-page":"eaav3942","DOI":"10.1126\/sciimmunol.aav3942","volume":"5","author":"M Hubert","year":"2020","unstructured":"Hubert, M. et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci. Immunol. 5, eaav3942 (2020).","journal-title":"Sci. Immunol."},{"key":"785_CR71","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature13590","volume":"514","author":"D Goubau","year":"2014","unstructured":"Goubau, D. et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5\u2019-diphosphates. Nature 514, 372\u2013375 (2014).","journal-title":"Nature"},{"key":"785_CR72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00262-018-2164-6","volume":"67","author":"H Sultan","year":"2018","unstructured":"Sultan, H., Wu, J., Kumai, T., Salazar, A. M. & Celis, E. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice. Cancer Immunol. Immunother. 67, 1091\u20131103 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature04734","volume":"441","author":"H Kato","year":"2006","unstructured":"Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101\u2013105 (2006).","journal-title":"Nature"},{"key":"785_CR74","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"785_CR75","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548\u2013569 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"785_CR76","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ijc.30159","volume":"139","author":"L Andzinski","year":"2016","unstructured":"Andzinski, L. et al. Growing tumors induce a local STING dependent type I IFN response in dendritic cells. Int. J. Cancer 139, 1350\u20131357 (2016).","journal-title":"Int. J. Cancer"},{"key":"785_CR77","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"785_CR78","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","volume":"47","author":"MM Xu","year":"2017","unstructured":"Xu, M. M. et al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity 47, 363\u2013373 e365 (2017).","journal-title":"Immunity"},{"key":"785_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04804-6","volume":"9","author":"H Guak","year":"2018","unstructured":"Guak, H. et al. Glycolytic metabolism is essential for CCR7 oligomerization and dendritic cell migration. Nat. Commun. 9, 2463 (2018).","journal-title":"Nat. Commun."},{"key":"785_CR80","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/intimm\/dxq435","volume":"22","author":"LA Johnson","year":"2010","unstructured":"Johnson, L. A. & Jackson, D. G. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int. Immunol. 22, 839\u2013849 (2010).","journal-title":"Int. Immunol."},{"key":"785_CR81","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1182\/blood-2009-10-249540","volume":"115","author":"CM Krawczyk","year":"2010","unstructured":"Krawczyk, C. M. et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115, 4742\u20134749 (2010).","journal-title":"Blood"},{"key":"785_CR82","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2012-03-419747","volume":"120","author":"B Everts","year":"2012","unstructured":"Everts, B. et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 120, 1422\u20131431 (2012).","journal-title":"Blood"},{"key":"785_CR83","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.1228456","volume":"339","author":"M Weber","year":"2013","unstructured":"Weber, M. et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339, 328\u2013332 (2013).","journal-title":"Science"},{"key":"785_CR84","first-page":"12","volume":"63","author":"IJ De Vries","year":"2003","unstructured":"De Vries, I. J. et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63, 12\u201317 (2003).","journal-title":"Cancer Res."},{"key":"785_CR85","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","volume":"184","author":"M Di Pilato","year":"2021","unstructured":"Di Pilato, M. et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell 184, 4512\u20134530.e4522 (2021).","journal-title":"Cell"},{"key":"785_CR86","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","volume":"21","author":"JJ Engelhardt","year":"2012","unstructured":"Engelhardt, J. J. et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402\u2013417 (2012).","journal-title":"Cancer Cell"},{"key":"785_CR87","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.26.021607.090254","volume":"26","author":"GJ Randolph","year":"2008","unstructured":"Randolph, G. J., Ochando, J. & Partida-Sanchez, S. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26, 293\u2013316 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"785_CR88","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/eji.200939548","volume":"39","author":"MB Lutz","year":"2009","unstructured":"Lutz, M. B. & Kurts, C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur. J. Immunol. 39, 2325\u20132330 (2009).","journal-title":"Eur. J. Immunol."},{"key":"785_CR89","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.it.2004.09.013","volume":"25","author":"FR Carbone","year":"2004","unstructured":"Carbone, F. R., Belz, G. T. & Heath, W. R. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 25, 655\u2013658 (2004).","journal-title":"Trends Immunol."},{"key":"785_CR90","doi-asserted-by":"publisher","first-page":"eabd3774","DOI":"10.1126\/sciimmunol.abd3774","volume":"6","author":"T Joeris","year":"2021","unstructured":"Joeris, T. et al. Intestinal cDC1 drive cross-tolerance to epithelial-derived antigen via induction of FoxP3+CD8+ Tregs. Sci. Immunol. 6, eabd3774 (2021).","journal-title":"Sci. Immunol."},{"key":"785_CR91","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","volume":"7","author":"SK Wculek","year":"2019","unstructured":"Wculek, S. K. et al. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. J. Immunother. Cancer 7, 100 (2019). A seminal study demonstrating the in vivo antitumour vaccination efficacy of ex vivo tumour-lysate-loaded cDC1s.","journal-title":"J. Immunother. Cancer"},{"key":"785_CR92","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/30845","volume":"393","author":"A Lanzavecchia","year":"1998","unstructured":"Lanzavecchia, A. Immunology. Licence to kill. Nature 393, 413\u2013414 (1998).","journal-title":"Nature"},{"key":"785_CR93","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/30989","volume":"393","author":"JP Ridge","year":"1998","unstructured":"Ridge, J. P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474\u2013478 (1998).","journal-title":"Nature"},{"key":"785_CR94","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions. Nature 393, 480\u2013483 (1998).","journal-title":"Nature"},{"key":"785_CR95","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","volume":"393","author":"SR Bennett","year":"1998","unstructured":"Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478\u2013480 (1998).","journal-title":"Nature"},{"key":"785_CR96","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1074-7613(03)00230-9","volume":"19","author":"T Kobayashi","year":"2003","unstructured":"Kobayashi, T. et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19, 353\u2013363 (2003).","journal-title":"Immunity"},{"key":"785_CR97","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","volume":"179","author":"F Sallusto","year":"1994","unstructured":"Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109\u20131118 (1994).","journal-title":"J. Exp. Med."},{"key":"785_CR98","doi-asserted-by":"publisher","first-page":"108189","DOI":"10.1016\/j.pharmthera.2022.108189","volume":"239","author":"A Cirella","year":"2022","unstructured":"Cirella, A. et al. Novel strategies exploiting interleukin-12 in cancer immunotherapy. Pharmacol. Ther. 239, 108189 (2022).","journal-title":"Pharmacol. Ther."},{"key":"785_CR99","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ni1071","volume":"5","author":"WS Hou","year":"2004","unstructured":"Hou, W. S. & Van Parijs, L. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5, 583\u2013589 (2004).","journal-title":"Nat. Immunol."},{"key":"785_CR100","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/9.3.365","volume":"9","author":"P Bjorck","year":"1997","unstructured":"Bjorck, P., Banchereau, J. & Flores-Romo, L. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int. Immunol. 9, 365\u2013372 (1997).","journal-title":"Int. Immunol."},{"key":"785_CR101","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1084\/jem.20020861","volume":"196","author":"GT Belz","year":"2002","unstructured":"Belz, G. T. et al. The CD8alpha+ dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196, 1099\u20131104 (2002).","journal-title":"J. Exp. Med."},{"key":"785_CR102","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1084\/jem.191.3.411","volume":"191","author":"RM Steinman","year":"2000","unstructured":"Steinman, R. M., Turley, S., Mellman, I. & Inaba, K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191, 411\u2013416 (2000).","journal-title":"J. Exp. Med."},{"key":"785_CR103","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1172\/JCI63980","volume":"123","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J. Clin. Invest. 123, 1999\u20132010 (2013).","journal-title":"J. Clin. Invest."},{"key":"785_CR104","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/ni.1602","volume":"9","author":"T Di Pucchio","year":"2008","unstructured":"Di Pucchio, T. et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat. Immunol. 9, 551\u2013557 (2008).","journal-title":"Nat. Immunol."},{"key":"785_CR105","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00262-012-1210-z","volume":"61","author":"J Tel","year":"2012","unstructured":"Tel, J., van der Leun, A. M., Figdor, C. G., Torensma, R. & de Vries, I. J. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol. Immunother. 61, 1279\u20131288 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR106","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood-2012-06-435644","volume":"121","author":"J Tel","year":"2013","unstructured":"Tel, J. et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121, 459\u2013467 (2013).","journal-title":"Blood"},{"key":"785_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45358-0","volume":"15","author":"KF Bol","year":"2024","unstructured":"Bol, K. F. et al. Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial. Nat. Commun. 15, 1632 (2024).","journal-title":"Nat. Commun."},{"key":"785_CR108","doi-asserted-by":"publisher","first-page":"2015113","DOI":"10.1080\/2162402X.2021.2015113","volume":"11","author":"M Bloemendal","year":"2022","unstructured":"Bloemendal, M. et al. Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. Oncoimmunology 11, 2015113 (2022).","journal-title":"Oncoimmunology"},{"key":"785_CR109","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1108003","volume":"307","author":"L Delamarre","year":"2005","unstructured":"Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307, 1630\u20131634 (2005).","journal-title":"Science"},{"key":"785_CR110","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1084\/jem.20051106","volume":"202","author":"D Accapezzato","year":"2005","unstructured":"Accapezzato, D. et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J. Exp. Med. 202, 817\u2013828 (2005).","journal-title":"J. Exp. Med."},{"key":"785_CR111","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1126\/science.7809629","volume":"267","author":"M Kovacsovics-Bankowski","year":"1995","unstructured":"Kovacsovics-Bankowski, M. & Rock, K. L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243\u2013246 (1995).","journal-title":"Science"},{"key":"785_CR112","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1074-7613(00)80248-4","volume":"4","author":"AY Huang","year":"1996","unstructured":"Huang, A. Y., Bruce, A. T., Pardoll, D. M. & Levitsky, H. I. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4, 349\u2013355 (1996).","journal-title":"Immunity"},{"key":"785_CR113","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/14058","volume":"1","author":"A Rodriguez","year":"1999","unstructured":"Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. & Amigorena, S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1, 362\u2013368 (1999).","journal-title":"Nat. Cell Biol."},{"key":"785_CR114","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1073\/pnas.0712394105","volume":"105","author":"ML Lin","year":"2008","unstructured":"Lin, M. L. et al. Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proc. Natl Acad. Sci. USA 105, 3029\u20133034 (2008). Through injecting the pro-apoptotic protein cytochrome c into mice, this study showed that it was possible to deplete cells that have an endosome to cytosol shuttle mechanism. This is also the first study to demonstrate that cDC1s are the main and potentially only cell subset capable of efficiently transporting engulfed antigens to the cytosol for cross-presentation.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR115","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2006.08.017","volume":"25","author":"AL Ackerman","year":"2006","unstructured":"Ackerman, A. L., Giodini, A. & Cresswell, P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25, 607\u2013617 (2006).","journal-title":"Immunity"},{"key":"785_CR116","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.immuni.2015.04.008","volume":"42","author":"M Zehner","year":"2015","unstructured":"Zehner, M. et al. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8+ T cells. Immunity 42, 850\u2013863 (2015).","journal-title":"Immunity"},{"key":"785_CR117","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.cell.2011.11.021","volume":"147","author":"I Cebrian","year":"2011","unstructured":"Cebrian, I. et al. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell 147, 1355\u20131368 (2011).","journal-title":"Cell"},{"key":"785_CR118","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1084\/jem.20170229","volume":"214","author":"A Alloatti","year":"2017","unstructured":"Alloatti, A. et al. Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. J. Exp. Med. 214, 2231\u20132241 (2017).","journal-title":"J. Exp. Med."},{"key":"785_CR119","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.4049\/jimmunol.173.10.5929","volume":"173","author":"H Zheng","year":"2004","unstructured":"Zheng, H. & Li, Z. Cutting edge: cross-presentation of cell-associated antigens to MHC class I molecule is regulated by a major transcription factor for heat shock proteins. J. Immunol. 173, 5929\u20135933 (2004).","journal-title":"J. Immunol."},{"key":"785_CR120","doi-asserted-by":"publisher","first-page":"16363","DOI":"10.1073\/pnas.1108372108","volume":"108","author":"T Imai","year":"2011","unstructured":"Imai, T. et al. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl Acad. Sci. USA 108, 16363\u201316368 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR121","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.4049\/jimmunol.1000821","volume":"185","author":"T Ichiyanagi","year":"2010","unstructured":"Ichiyanagi, T. et al. Essential role of endogenous heat shock protein 90 of dendritic cells in antigen cross-presentation. J. Immunol. 185, 2693\u20132700 (2010).","journal-title":"J. Immunol."},{"key":"785_CR122","first-page":"745962","volume":"2012","author":"Y Kato","year":"2012","unstructured":"Kato, Y. et al. HSP70 and HSP90 differentially regulate translocation of extracellular antigen to the cytosol for cross-presentation. Autoimmune Dis. 2012, 745962 (2012).","journal-title":"Autoimmune Dis."},{"key":"785_CR123","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.aat5030","volume":"362","author":"DJ Theisen","year":"2018","unstructured":"Theisen, D. J. et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science 362, 694\u2013699 (2018). This study identifies WDFY4 as a crucial protein involved in antigen presentation by using functional genomic screening techniques and in vitro cross-priming assays. Furthermore, the generation of WDFY4\u2212\/\u2212 mice lacking the ability to cross-present viral and tumour-associated antigens provides a suitable model to establish the relevance of cross-presentation in tumour immunology.","journal-title":"Science"},{"key":"785_CR124","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1126\/science.adg8802","volume":"380","author":"P Rodriguez-Silvestre","year":"2023","unstructured":"Rodriguez-Silvestre, P. et al. Perforin-2 is a pore-forming effector of endocytic escape in cross-presenting dendritic cells. Science 380, 1258\u20131265 (2023). This study identifies perforin 2 as a key pore-forming protein required for escape of proteins or peptides from endosomes in cDC1s and demonstrates that mice lacking perforin 2 are unable to effectively prime CD8+ T cells against cell-associated antigens.","journal-title":"Science"},{"key":"785_CR125","doi-asserted-by":"publisher","first-page":"eadn2168","DOI":"10.1126\/sciimmunol.adn2168","volume":"9","author":"GA Gonzales","year":"2024","unstructured":"Gonzales, G. A. et al. The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells. Sci. Immunol. 9, eadn2168 (2024).","journal-title":"Sci. Immunol."},{"key":"785_CR126","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41590-020-00824-x","volume":"22","author":"J Canton","year":"2021","unstructured":"Canton, J. et al. The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat. Immunol. 22, 140\u2013153 (2021).","journal-title":"Nat. Immunol."},{"key":"785_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238484","volume":"15","author":"SC Nalle","year":"2020","unstructured":"Nalle, S. C. et al. Aquaporin-3 regulates endosome-to-cytosol transfer via lipid peroxidation for cross presentation. PLoS ONE 15, e0238484 (2020).","journal-title":"PLoS ONE"},{"key":"785_CR128","doi-asserted-by":"publisher","first-page":"111205","DOI":"10.1016\/j.celrep.2022.111205","volume":"40","author":"M Gros","year":"2022","unstructured":"Gros, M. et al. Endocytic membrane repair by ESCRT-III controls antigen export to the cytosol during antigen cross-presentation. Cell Rep. 40, 111205 (2022).","journal-title":"Cell Rep."},{"key":"785_CR129","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1016\/S0021-9258(18)53472-4","volume":"268","author":"D Bromme","year":"1993","unstructured":"Bromme, D. et al. Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. J. Biol. Chem. 268, 4832\u20134838 (1993).","journal-title":"J. Biol. Chem."},{"key":"785_CR130","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1126\/science.1172845","volume":"325","author":"L Saveanu","year":"2009","unstructured":"Saveanu, L. et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 325, 213\u2013217 (2009).","journal-title":"Science"},{"key":"785_CR131","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.immuni.2004.07.004","volume":"21","author":"L Shen","year":"2004","unstructured":"Shen, L., Sigal, L. J., Boes, M. & Rock, K. L. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21, 155\u2013165 (2004).","journal-title":"Immunity"},{"key":"785_CR132","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.4049\/jimmunol.1302312","volume":"191","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. Enhanced endoplasmic reticulum entry of tumor antigen is crucial for cross-presentation induced by dendritic cell-targeted vaccination. J. Immunol. 191, 6010\u20136021 (2013).","journal-title":"J. Immunol."},{"key":"785_CR133","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.3390\/cells10123360","volume":"10","author":"BL van den Eshof","year":"2021","unstructured":"van den Eshof, B. L., Medfai, L., Nolfi, E., Wawrzyniuk, M. & Sijts, A. The function of immunoproteasomes-an immunologists\u2019 perspective. Cells 10, 3360 (2021).","journal-title":"Cells"},{"key":"785_CR134","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.4049\/jimmunol.156.11.4182","volume":"156","author":"R Song","year":"1996","unstructured":"Song, R. & Harding, C. V. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J. Immunol. 156, 4182\u20134190 (1996).","journal-title":"J. Immunol."},{"key":"785_CR135","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.4049\/jimmunol.177.6.3525","volume":"177","author":"S Bertholet","year":"2006","unstructured":"Bertholet, S. et al. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J. Immunol. 177, 3525\u20133533 (2006).","journal-title":"J. Immunol."},{"key":"785_CR136","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/361359a0","volume":"361","author":"JD Pfeifer","year":"1993","unstructured":"Pfeifer, J. D. et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361, 359\u2013362 (1993).","journal-title":"Nature"},{"key":"785_CR137","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/eji.1830250637","volume":"25","author":"MF Bachmann","year":"1995","unstructured":"Bachmann, M. F. et al. TAP1-independent loading of class I molecules by exogenous viral proteins. Eur. J. Immunol. 25, 1739\u20131743 (1995).","journal-title":"Eur. J. Immunol."},{"key":"785_CR138","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899266","volume":"38","author":"D Sengupta","year":"2019","unstructured":"Sengupta, D., Graham, M., Liu, X. & Cresswell, P. Proteasomal degradation within endocytic organelles mediates antigen cross-presentation. EMBO J. 38, e99266 (2019).","journal-title":"EMBO J."},{"key":"785_CR139","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201900464","volume":"2","author":"S Montealegre","year":"2019","unstructured":"Montealegre, S., Abramova, A., Manceau, V., de Kanter, A. F. & van Endert, P. The role of MHC class I recycling and Arf6 in cross-presentation by murine dendritic cells. Life Sci. Alliance 2, e201900464 (2019).","journal-title":"Life Sci. Alliance"},{"key":"785_CR140","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41590-021-00903-7","volume":"22","author":"G Barbet","year":"2021","unstructured":"Barbet, G. et al. TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming. Nat. Immunol. 22, 497\u2013509 (2021).","journal-title":"Nat. Immunol."},{"key":"785_CR141","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2014.04.054","volume":"158","author":"P Nair-Gupta","year":"2014","unstructured":"Nair-Gupta, P. et al. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. Cell 158, 506\u2013521 (2014).","journal-title":"Cell"},{"key":"785_CR142","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","volume":"19","author":"TL Murphy","year":"2022","unstructured":"Murphy, T. L. & Murphy, K. M. Dendritic cells in cancer immunology. Cell Mol. Immunol. 19, 3\u201313 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"785_CR143","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity 54, 2338\u20132353 e2336 (2021).","journal-title":"Immunity"},{"key":"785_CR144","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065X.2009.00784.x","volume":"229","author":"AH Sharpe","year":"2009","unstructured":"Sharpe, A. H. Mechanisms of costimulation. Immunol. Rev. 229, 5\u201311 (2009).","journal-title":"Immunol. Rev."},{"key":"785_CR145","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","volume":"57","author":"KP Burke","year":"2024","unstructured":"Burke, K. P., Chaudhri, A., Freeman, G. J. & Sharpe, A. H. The B7:CD28 family and friends: unraveling coinhibitory interactions. Immunity 57, 223\u2013244 (2024).","journal-title":"Immunity"},{"key":"785_CR146","doi-asserted-by":"publisher","first-page":"114141","DOI":"10.1016\/j.celrep.2024.114141","volume":"43","author":"A Ziblat","year":"2024","unstructured":"Ziblat, A. et al. Batf3+ DCs and the 4-1BB\/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1\/PD-L1 blockade efficacy. Cell Rep. 43, 114141 (2024).","journal-title":"Cell Rep."},{"key":"785_CR147","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","volume":"13","author":"I Melero","year":"2023","unstructured":"Melero, I. et al. CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary. Cancer Discov. 13, 552\u2013569 (2023).","journal-title":"Cancer Discov."},{"key":"785_CR148","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cellimm.2003.11.003","volume":"226","author":"D Laderach","year":"2003","unstructured":"Laderach, D., Wesa, A. & Galy, A. 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol. 226, 37\u201344 (2003).","journal-title":"Cell Immunol."},{"key":"785_CR149","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4049\/jimmunol.174.2.710","volume":"174","author":"TN Bullock","year":"2005","unstructured":"Bullock, T. N. & Yagita, H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J. Immunol. 174, 710\u2013717 (2005).","journal-title":"J. Immunol."},{"key":"785_CR150","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.4049\/jimmunol.178.3.1564","volume":"178","author":"PJ Sanchez","year":"2007","unstructured":"Sanchez, P. J., McWilliams, J. A., Haluszczak, C., Yagita, H. & Kedl, R. M. Combined TLR\/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 178, 1564\u20131572 (2007).","journal-title":"J. Immunol."},{"key":"785_CR151","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41590-022-01324-w","volume":"23","author":"R Wu","year":"2022","unstructured":"Wu, R. et al. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat. Immunol. 23, 1536\u20131550 (2022).","journal-title":"Nat. Immunol."},{"key":"785_CR152","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/80877","volume":"1","author":"J Hendriks","year":"2000","unstructured":"Hendriks, J. et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1, 433\u2013440 (2000).","journal-title":"Nat. Immunol."},{"key":"785_CR153","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.immuni.2008.10.009","volume":"29","author":"AM Keller","year":"2008","unstructured":"Keller, A. M., Schildknecht, A., Xiao, Y., van den Broek, M. & Borst, J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29, 934\u2013946 (2008).","journal-title":"Immunity"},{"key":"785_CR154","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/imt.15.32","volume":"7","author":"K van de Ven","year":"2015","unstructured":"van de Ven, K. & Borst, J. Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy 7, 655\u2013667 (2015).","journal-title":"Immunotherapy"},{"key":"785_CR155","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1084\/jem.20091711","volume":"207","author":"J McGill","year":"2010","unstructured":"McGill, J., Van Rooijen, N. & Legge, K. L. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J. Exp. Med. 207, 521\u2013534 (2010).","journal-title":"J. Exp. Med."},{"key":"785_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123340","volume":"10","author":"S Anguille","year":"2015","unstructured":"Anguille, S. et al. Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-dependent manner. PLoS ONE 10, e0123340 (2015).","journal-title":"PLoS ONE"},{"key":"785_CR157","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.4049\/jimmunol.1203149","volume":"190","author":"T Sosinowski","year":"2013","unstructured":"Sosinowski, T. et al. CD8alpha+ dendritic cell trans presentation of IL-15 to naive CD8+ T cells produces antigen-inexperienced T cells in the periphery with memory phenotype and function. J. Immunol. 190, 1936\u20131947 (2013).","journal-title":"J. Immunol."},{"key":"785_CR158","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.immuni.2011.08.008","volume":"35","author":"M Mashayekhi","year":"2011","unstructured":"Mashayekhi, M. et al. CD8alpha+ dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity 35, 249\u2013259 (2011).","journal-title":"Immunity"},{"key":"785_CR159","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/eji.201444651","volume":"45","author":"M Martinez-Lopez","year":"2015","unstructured":"Martinez-Lopez, M., Iborra, S., Conde-Garrosa, R. & Sancho, D. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur. J. Immunol. 45, 119\u2013129 (2015).","journal-title":"Eur. J. Immunol."},{"key":"785_CR160","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/7403","volume":"5","author":"NC Fernandez","year":"1999","unstructured":"Fernandez, N. C. et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5, 405\u2013411 (1999).","journal-title":"Nat. Med."},{"key":"785_CR161","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1182\/blood-2004-01-0380","volume":"104","author":"C Borg","year":"2004","unstructured":"Borg, C. et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 104, 3267\u20133275 (2004).","journal-title":"Blood"},{"key":"785_CR162","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/14728222.2023.2287574","volume":"27","author":"A Cirella","year":"2023","unstructured":"Cirella, A. et al. Interleukin-18 in cancer immunology and immunotherapy. Expert Opin. Ther. Targets 27, 1035\u20131042 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"key":"785_CR163","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 (2020).","journal-title":"Nature"},{"key":"785_CR164","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","volume":"41","author":"P Meiser","year":"2023","unstructured":"Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498\u20131515.e10 (2023).","journal-title":"Cancer Cell"},{"key":"785_CR165","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"785_CR166","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 e110 (2019).","journal-title":"Immunity"},{"key":"785_CR167","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1182\/blood-2005-07-2696","volume":"107","author":"D Pende","year":"2006","unstructured":"Pende, D. et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107, 2030\u20132036 (2006).","journal-title":"Blood"},{"key":"785_CR168","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.smim.2023.101710","volume":"66","author":"F Chatterjee","year":"2023","unstructured":"Chatterjee, F. & Spranger, S. MHC-dressing on dendritic cells: boosting anti-tumor immunity via unconventional tumor antigen presentation. Semin. Immunol. 66, 101710 (2023).","journal-title":"Semin. Immunol."},{"key":"785_CR169","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","volume":"55","author":"BW MacNabb","year":"2022","unstructured":"MacNabb, B. W. et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity 55, 982\u2013997 e988 (2022).","journal-title":"Immunity"},{"key":"785_CR170","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/2326-6066.CIR-20-0248","volume":"8","author":"A Das Mohapatra","year":"2020","unstructured":"Das Mohapatra, A. et al. Cross-dressing of CD8alpha+ dendritic cells with antigens from live mouse tumor cells is a major mechanism of cross-priming. Cancer Immunol. Res. 8, 1287\u20131299 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR171","doi-asserted-by":"publisher","first-page":"102331","DOI":"10.1016\/j.coi.2023.102331","volume":"83","author":"P Schriek","year":"2023","unstructured":"Schriek, P. & Villadangos, J. A. Trogocytosis and cross-dressing in antigen presentation. Curr. Opin. Immunol. 83, 102331 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"785_CR172","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1146\/annurev.immunol.23.021704.115702","volume":"23","author":"JW Yewdell","year":"2005","unstructured":"Yewdell, J. W. & Haeryfar, S. M. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23, 651\u2013682 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"785_CR173","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.ai.2023.07.001","volume":"159","author":"BW MacNabb","year":"2023","unstructured":"MacNabb, B. W. & Kline, J. MHC cross-dressing in antigen presentation. Adv. Immunol. 159, 115\u2013147 (2023).","journal-title":"Adv. Immunol."},{"key":"785_CR174","first-page":"308","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell. Immun. Immun. 55, 308\u2013323 e309 (2022).","journal-title":"Immun. Immun."},{"key":"785_CR175","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216 e1208 (2024).","journal-title":"Cancer Cell"},{"key":"785_CR176","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","volume":"135","author":"B Mastelic-Gavillet","year":"2020","unstructured":"Mastelic-Gavillet, B. et al. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. Eur. J. Cancer 135, 173\u2013182 (2020).","journal-title":"Eur. J. Cancer"},{"key":"785_CR177","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221757","volume":"220","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. IL-6 selectively suppresses cDC1 specification via C\/EBPbeta. J. Exp. Med. 220, e20221757 (2023).","journal-title":"J. Exp. Med."},{"key":"785_CR178","doi-asserted-by":"publisher","first-page":"101696","DOI":"10.1016\/j.xcrm.2024.101696","volume":"5","author":"MS Alam","year":"2024","unstructured":"Alam, M. S. et al. TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function. Cell Rep. Med. 5, 101696 (2024).","journal-title":"Cell Rep. Med."},{"key":"785_CR179","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/2159-8290.CD-21-1115","volume":"12","author":"I Olivera","year":"2022","unstructured":"Olivera, I. et al. A therapeutically actionable protumoral axis of cytokines involving IL-8, TNFalpha, and IL-1beta. Cancer Discov. 12, 2140\u20132157 (2022).","journal-title":"Cancer Discov."},{"key":"785_CR180","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.163.6.3260","volume":"163","author":"JE Ohm","year":"1999","unstructured":"Ohm, J. E. et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J. Immunol. 163, 3260\u20133268 (1999).","journal-title":"J. Immunol."},{"key":"785_CR181","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","volume":"160","author":"T Oyama","year":"1998","unstructured":"Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160, 1224\u20131232 (1998).","journal-title":"J. Immunol."},{"key":"785_CR182","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/cas.14091","volume":"110","author":"J Long","year":"2019","unstructured":"Long, J. et al. Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway. Cancer Sci. 110, 2357\u20132367 (2019).","journal-title":"Cancer Sci."},{"key":"785_CR183","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"785_CR184","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.4049\/jimmunol.166.7.4312","volume":"166","author":"S Corinti","year":"2001","unstructured":"Corinti, S., Albanesi, C., la Sala, A., Pastore, S. & Girolomoni, G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166, 4312\u20134318 (2001).","journal-title":"J. Immunol."},{"key":"785_CR185","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","volume":"13","author":"M Tang","year":"2015","unstructured":"Tang, M. et al. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 13, 2851\u20132864 (2015).","journal-title":"Cell Rep."},{"key":"785_CR186","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.4049\/jimmunol.173.6.3844","volume":"173","author":"SJ Park","year":"2004","unstructured":"Park, S. J. et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173, 3844\u20133854 (2004).","journal-title":"J. Immunol."},{"key":"785_CR187","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190673","volume":"217","author":"JH Lin","year":"2020","unstructured":"Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. 217, e20190673 (2020).","journal-title":"J. Exp. Med."},{"key":"785_CR188","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massague, J. Transforming growth factor-beta signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"785_CR189","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-9966-31-3","volume":"31","author":"K Imai","year":"2012","unstructured":"Imai, K. et al. Inhibition of dendritic cell migration by transforming growth factor-beta1 increases tumor-draining lymph node metastasis. J. Exp. Clin. Cancer Res. 31, 3 (2012).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"785_CR190","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood.V93.10.3225.410k25_3225_3232","volume":"93","author":"M Ogata","year":"1999","unstructured":"Ogata, M. et al. Chemotactic response toward chemokines and its regulation by transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells. Blood 93, 3225\u20133232 (1999).","journal-title":"Blood"},{"key":"785_CR191","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ni.2077","volume":"12","author":"MT Pallotta","year":"2011","unstructured":"Pallotta, M. T. et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12, 870\u2013878 (2011).","journal-title":"Nat. Immunol."},{"key":"785_CR192","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2022.05.013","volume":"55","author":"M Gargaro","year":"2022","unstructured":"Gargaro, M. et al. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity 55, 1032\u20131050 e1014 (2022).","journal-title":"Immunity"},{"key":"785_CR193","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell, T. C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase i results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037). J. Clin. Oncol. 36, 3223\u20133230 (2018).","journal-title":"J. Clin. Oncol."},{"key":"785_CR194","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4049\/jimmunol.160.1.233","volume":"160","author":"JF Piskurich","year":"1998","unstructured":"Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C. & Ting, J. P. Identification of distinct regions of 5\u2019 flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J. Immunol. 160, 233\u2013240 (1998).","journal-title":"J. Immunol."},{"key":"785_CR195","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.4049\/jimmunol.158.3.1095","volume":"158","author":"D Nandan","year":"1997","unstructured":"Nandan, D. & Reiner, N. E. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J. Immunol. 158, 1095\u20131101 (1997).","journal-title":"J. Immunol."},{"key":"785_CR196","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1172\/JCI65745","volume":"123","author":"BA Hanks","year":"2013","unstructured":"Hanks, B. A. et al. Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J. Clin. Invest. 123, 3925\u20133940 (2013).","journal-title":"J. Clin. Invest."},{"key":"785_CR197","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.7150\/thno.44567","volume":"10","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. TGF-beta causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics 10, 7656\u20137670 (2020).","journal-title":"Theranostics"},{"key":"785_CR198","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 13, 2448\u20132469 (2023).","journal-title":"Cancer Discov."},{"key":"785_CR199","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.4049\/jimmunol.0712671","volume":"182","author":"IE Dumitriu","year":"2009","unstructured":"Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T. & Gregory, C. D. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 182, 2795\u20132807 (2009).","journal-title":"J. Immunol."},{"key":"785_CR200","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03600-6","volume":"9","author":"MA Meyer","year":"2018","unstructured":"Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250 (2018).","journal-title":"Nat. Commun."},{"key":"785_CR201","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341\u20131358 e1311 (2023).","journal-title":"Immunity"},{"key":"785_CR202","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell\u00a0162, 1257\u20131270\u00a0(2015).","journal-title":"Cell"},{"key":"785_CR203","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/gutjnl-2020-322924","volume":"71","author":"TX Huang","year":"2022","unstructured":"Huang, T. X. et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut 71, 333\u2013344 (2022).","journal-title":"Gut"},{"key":"785_CR204","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/j.seminoncol.2015.02.009","volume":"42","author":"S Labiano","year":"2015","unstructured":"Labiano, S., Palazon, A. & Melero, I. Immune response regulation in the tumor microenvironment by hypoxia. Semin. Oncol. 42, 378\u2013386 (2015).","journal-title":"Semin. Oncol."},{"key":"785_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21891-z","volume":"8","author":"A Hammami","year":"2018","unstructured":"Hammami, A., Abidin, B. M., Heinonen, K. M. & Stager, S. HIF-1alpha hampers dendritic cell function and Th1 generation during chronic visceral leishmaniasis. Sci. Rep. 8, 3500 (2018).","journal-title":"Sci. Rep."},{"key":"785_CR206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244366","volume":"15","author":"CW Tran","year":"2020","unstructured":"Tran, C. W. et al. Hypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity. PLoS ONE 15, e0244366 (2020).","journal-title":"PLoS ONE"},{"key":"785_CR207","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI0215337","volume":"110","author":"K Synnestvedt","year":"2002","unstructured":"Synnestvedt, K. et al. Ecto-5\u2019-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993\u20131002 (2002).","journal-title":"J. Clin. Invest."},{"key":"785_CR208","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","volume":"187","author":"SM Fendt","year":"2024","unstructured":"Fendt, S. M. 100 years of the Warburg effect: a cancer metabolism endeavor. Cell 187, 3824\u20133828 (2024).","journal-title":"Cell"},{"key":"785_CR209","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013\u20132021 (2006).","journal-title":"Blood"},{"key":"785_CR210","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41388-020-1216-5","volume":"39","author":"TP Brown","year":"2020","unstructured":"Brown, T. P. et al. The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment. Oncogene 39, 3292\u20133304 (2020).","journal-title":"Oncogene"},{"key":"785_CR211","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.15252\/embj.201694695","volume":"35","author":"P Hanc","year":"2016","unstructured":"Hanc, P. et al. A pH- and ionic strength-dependent conformational change in the neck region regulates DNGR-1 function in dendritic cells. EMBO J. 35, 2484\u20132497 (2016).","journal-title":"EMBO J."},{"key":"785_CR212","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","volume":"620","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature 620, 200\u2013208 (2023).","journal-title":"Nature"},{"key":"785_CR213","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880\u2013886 (2010).","journal-title":"Nat. Med."},{"key":"785_CR214","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.4049\/jimmunol.1302801","volume":"192","author":"R Ramakrishnan","year":"2014","unstructured":"Ramakrishnan, R. et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J. Immunol. 192, 2920\u20132931 (2014).","journal-title":"J. Immunol."},{"key":"785_CR215","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"785_CR216","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nm.2074","volume":"16","author":"EJ Villablanca","year":"2010","unstructured":"Villablanca, E. J. et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16, 98\u2013105 (2010).","journal-title":"Nat. Med."},{"key":"785_CR217","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3389\/fimmu.2019.02702","volume":"10","author":"LS Carstensen","year":"2019","unstructured":"Carstensen, L. S. et al. Long-term exposure to inflammation induces differential cytokine patterns and apoptosis in dendritic cells. Front. Immunol. 10, 2702 (2019).","journal-title":"Front. Immunol."},{"key":"785_CR218","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.4049\/jimmunol.1102868","volume":"188","author":"K Abdi","year":"2012","unstructured":"Abdi, K., Singh, N. J. & Matzinger, P. Lipopolysaccharide-activated dendritic cells: \u201cexhausted\u201d or alert and waiting? J. Immunol. 188, 5981\u20135989 (2012).","journal-title":"J. Immunol."},{"key":"785_CR219","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1365-2567.2006.02474.x","volume":"120","author":"K Kajino","year":"2007","unstructured":"Kajino, K., Nakamura, I., Bamba, H., Sawai, T. & Ogasawara, K. Involvement of IL-10 in exhaustion of myeloid dendritic cells and rescue by CD40 stimulation. Immunology 120, 28\u201337 (2007).","journal-title":"Immunology"},{"key":"785_CR220","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41591-022-01779-2","volume":"28","author":"EM Park","year":"2022","unstructured":"Park, E. M. et al. Targeting the gut and tumor microbiota in cancer. Nat. Med. 28, 690\u2013703 (2022).","journal-title":"Nat. Med."},{"key":"785_CR221","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008). The first mouse model almost selectively lacking cDC1s, which was generated through knockout of the gene encoding the transcription factor BATF3. These mice show impaired virus-specific CD8+ T cell responses to West Nile virus infection and a reduced ability to reject highly immunogenic tumours that are spontaneously rejected in immunocompetent mice.","journal-title":"Science"},{"key":"785_CR222","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1546068","volume":"8","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. Oncoimmunology 8, e1546068 (2019).","journal-title":"Oncoimmunology"},{"key":"785_CR223","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00262-014-1548-5","volume":"63","author":"BR James","year":"2014","unstructured":"James, B. R., Brincks, E. L., Kucaba, T. A., Boon, L. & Griffith, T. S. Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8alpha dendritic cells. Cancer Immunol. Immunother. 63, 685\u2013697 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR224","doi-asserted-by":"publisher","first-page":"eaal1713","DOI":"10.1126\/sciimmunol.aal1713","volume":"2","author":"P Dai","year":"2017","unstructured":"Dai, P. et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci. Immunol. 2, eaal1713 (2017).","journal-title":"Sci. Immunol."},{"key":"785_CR225","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814\u2013824 (2019).","journal-title":"Nat. Med."},{"key":"785_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19192-z","volume":"11","author":"T Oba","year":"2020","unstructured":"Oba, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat. Commun. 11, 5415 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR227","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","volume":"7","author":"MA Aznar","year":"2019","unstructured":"Aznar, M. A. et al. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J. Immunother. Cancer 7, 116 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR228","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002953","volume":"9","author":"M Alvarez","year":"2021","unstructured":"Alvarez, M. et al. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J. Immunother. Cancer 9, e002953 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR229","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of t cell immunity in melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"785_CR230","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003351","volume":"9","author":"E Conde","year":"2021","unstructured":"Conde, E. et al. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. J. Immunother. Cancer 9, e003351 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19833-3","volume":"11","author":"NF Kuhn","year":"2020","unstructured":"Kuhn, N. F. et al. CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nat. Commun. 11, 6171 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR232","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"785_CR233","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","volume":"36","author":"I Etxeberria","year":"2019","unstructured":"Etxeberria, I. et al. Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T cells. Cancer Cell 36, 613\u2013629.e617 (2019).","journal-title":"Cancer Cell"},{"key":"785_CR234","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.xcrm.2023.100978","volume":"4","author":"I Olivera","year":"2023","unstructured":"Olivera, I. et al. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell Rep. Med. 4, 100978 (2023).","journal-title":"Cell Rep. Med."},{"key":"785_CR235","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s41590-020-0786-2","volume":"21","author":"MA Ataide","year":"2020","unstructured":"Ataide, M. A. et al. BATF3 programs CD8+ T cell memory. Nat. Immunol. 21, 1397\u20131407 (2020).","journal-title":"Nat. Immunol."},{"key":"785_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.157","volume":"49","author":"W Lee","year":"2017","unstructured":"Lee, W., Kim, H. S., Hwang, S. S. & Lee, G. R. The transcription factor Batf3 inhibits the differentiation of regulatory T cells in the periphery. Exp. Mol. Med. 49, e393 (2017).","journal-title":"Exp. Mol. Med."},{"key":"785_CR237","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature11531","volume":"490","author":"R Tussiwand","year":"2012","unstructured":"Tussiwand, R. et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490, 502\u2013507 (2012).","journal-title":"Nature"},{"key":"785_CR238","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1305","volume":"10","author":"R Mattiuz","year":"2021","unstructured":"Mattiuz, R. et al. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T-cell protective responses to breast cancer. Clin. Transl. Immunol. 10, e1305 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"785_CR239","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41590-019-0450-x","volume":"20","author":"V Durai","year":"2019","unstructured":"Durai, V. et al. Cryptic activation of an Irf8 enhancer governs cDC1 fate specification. Nat. Immunol. 20, 1161\u20131173 (2019).","journal-title":"Nat. Immunol."},{"key":"785_CR240","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"785_CR241","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41590-018-0145-8","volume":"19","author":"P Michea","year":"2018","unstructured":"Michea, P. et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat. Immunol. 19, 885\u2013897 (2018).","journal-title":"Nat. Immunol."},{"key":"785_CR242","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","volume":"113","author":"S Spranger","year":"2016","unstructured":"Spranger, S. et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl Acad. Sci. USA 113, E7759\u2013E7768 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR243","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681\u2013691 (2020).","journal-title":"Nat. Cancer"},{"key":"785_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR245","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00432-021-03845-7","volume":"148","author":"X Fang","year":"2022","unstructured":"Fang, X. et al. TCF-1+ PD-1+ CD8+ T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients. J. Cancer Res. Clin. Oncol. 148, 2653\u20132660 (2022).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"785_CR246","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"785_CR247","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/cancers13071525","volume":"13","author":"FJ Cueto","year":"2021","unstructured":"Cueto, F. J. & Sancho, D. The Flt3L\/Flt3 axis in dendritic cell biology and cancer immunotherapy. Cancers 13, 1525 (2021).","journal-title":"Cancers"},{"key":"785_CR248","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","volume":"184","author":"E Maraskovsky","year":"1996","unstructured":"Maraskovsky, E. et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953\u20131962 (1996).","journal-title":"J. Exp. Med."},{"key":"785_CR249","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1084\/jem.20161135","volume":"213","author":"G Breton","year":"2016","unstructured":"Breton, G. et al. Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. J. Exp. Med. 213, 2861\u20132870 (2016).","journal-title":"J. Exp. Med."},{"key":"785_CR250","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nm0697-625","volume":"3","author":"DH Lynch","year":"1997","unstructured":"Lynch, D. H. et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3, 625\u2013631 (1997).","journal-title":"Nat. Med."},{"key":"785_CR251","first-page":"3511","volume":"57","author":"K Chen","year":"1997","unstructured":"Chen, K. et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57, 3511\u20133516 (1997). This study is the first to demonstrate that FLT3L could be used to increase antitumour immune responses in mice.","journal-title":"Cancer Res."},{"key":"785_CR252","first-page":"6028","volume":"59","author":"PK Chakravarty","year":"1999","unstructured":"Chakravarty, P. K. et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 59, 6028\u20136032 (1999).","journal-title":"Cancer Res."},{"key":"785_CR253","first-page":"380","volume":"58","author":"C Esche","year":"1998","unstructured":"Esche, C., Subbotin, V. M., Maliszewski, C., Lotze, M. T. & Shurin, M. R. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58, 380\u2013383 (1998).","journal-title":"Cancer Res."},{"key":"785_CR254","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI200419762","volume":"113","author":"K Furumoto","year":"2004","unstructured":"Furumoto, K., Soares, L., Engleman, E. G. & Merad, M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774\u2013783 (2004).","journal-title":"J. Clin. Invest."},{"key":"785_CR255","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862\u2013870 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"785_CR256","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289\u2013307.e289 (2020).","journal-title":"Cancer Cell"},{"key":"785_CR257","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT01976585 (2022)."},{"key":"785_CR258","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT02129075 (2021)."},{"key":"785_CR259","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-020-00143-y","volume":"1","author":"N Bhardwaj","year":"2020","unstructured":"Bhardwaj, N. et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat. Cancer 1, 1204\u20131217 (2020).","journal-title":"Nat. Cancer"},{"key":"785_CR260","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171621","volume":"134","author":"B Lam","year":"2024","unstructured":"Lam, B. et al. In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy. J. Clin. Invest. 134, e171621 (2024).","journal-title":"J. Clin. Invest."},{"key":"785_CR261","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jim.2014.07.008","volume":"413","author":"H Tu","year":"2014","unstructured":"Tu, H. et al. Robust expansion of dendritic cells in vivo by hydrodynamic FLT3L-FC gene transfer. J. Immunol. Methods 413, 69\u201373 (2014).","journal-title":"J. Immunol. Methods"},{"key":"785_CR262","first-page":"1080","volume":"61","author":"CF Hung","year":"2001","unstructured":"Hung, C. F. et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 61, 1080\u20131088 (2001).","journal-title":"Cancer Res."},{"key":"785_CR263","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1016\/j.vaccine.2017.09.003","volume":"35","author":"J Li","year":"2017","unstructured":"Li, J. et al. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6\/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect. Vaccine 35, 6459\u20136467 (2017).","journal-title":"Vaccine"},{"key":"785_CR264","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/sj.bmt.1703816","volume":"31","author":"SN Robinson","year":"2003","unstructured":"Robinson, S. N. et al. Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice. Bone Marrow Transpl. 31, 361\u2013369 (2003).","journal-title":"Bone Marrow Transpl."},{"key":"785_CR265","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-23-2808","volume":"30","author":"AW Tolcher","year":"2024","unstructured":"Tolcher, A. W. et al. Phase I study of GS-3583, an FMS-like tyrosine kinase 3 agonist Fc fusion protein, in patients with advanced solid tumors. Clin. Cancer Res. 30, 2954\u20132963 (2024).","journal-title":"Clin. Cancer Res."},{"key":"785_CR266","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1158\/0008-5472.CAN-18-0933","volume":"78","author":"AR Sanchez-Paulete","year":"2018","unstructured":"Sanchez-Paulete, A. R. et al. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus-derived vectors fosters dendritic cell-mediated T-cell cross-priming. Cancer Res. 78, 6643\u20136654 (2018). A phase Ib clinical trial evaluates a FLT3 agonist\u2013Fc fusion GS-3583, demonstrating good tolerability and the promotion of dose-dependent peripheral expansion of cDCs in patients with advanced solid tumours.","journal-title":"Cancer Res."},{"key":"785_CR267","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT01811992 (2024)."},{"key":"785_CR268","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.ymthe.2004.08.025","volume":"10","author":"S Ali","year":"2004","unstructured":"Ali, S. et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther. 10, 1071\u20131084 (2004).","journal-title":"Mol. Ther."},{"key":"785_CR269","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000325","volume":"8","author":"L Minute","year":"2020","unstructured":"Minute, L. et al. Cellular cytotoxicity is a form of immunogenic cell death. J. Immunother. Cancer 8, e000325 (2020). This study identifies CD8+ T cell- and NK cell-mediated cytotoxicity as a key mechanism of immunogenic cell death leading to cross-priming against tumour antigens.","journal-title":"J. Immunother. Cancer"},{"key":"785_CR270","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/eji.201242603","volume":"43","author":"O Klein","year":"2013","unstructured":"Klein, O. et al. Flt3 ligand expands CD4+FoxP3+ regulatory T cells in human subjects. Eur. J. Immunol. 43, 533\u2013539 (2013).","journal-title":"Eur. J. Immunol."},{"key":"785_CR271","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","volume":"187","author":"Y Shapir Itai","year":"2024","unstructured":"Shapir Itai, Y. et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell 187, 375\u2013389 e318 (2024).","journal-title":"Cell"},{"key":"785_CR272","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41551-021-00800-2","volume":"5","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat. Biomed. Eng. 5, 1261\u20131273 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"785_CR273","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","volume":"3","author":"R Salomon","year":"2022","unstructured":"Salomon, R. et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat. Cancer 3, 287\u2013302 (2022).","journal-title":"Nat. Cancer"},{"key":"785_CR274","doi-asserted-by":"publisher","first-page":"eadd4817","DOI":"10.1126\/sciimmunol.add4817","volume":"8","author":"O Zimmermannova","year":"2023","unstructured":"Zimmermannova, O. et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci. Immunol. 8, eadd4817 (2023).","journal-title":"Sci. Immunol."},{"key":"785_CR275","doi-asserted-by":"publisher","first-page":"eadn9083","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2024","unstructured":"Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024).","journal-title":"Science"},{"key":"785_CR276","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1084\/jem.20021598","volume":"196","author":"L Bonifaz","year":"2002","unstructured":"Bonifaz, L. et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627\u20131638 (2002).","journal-title":"J. Exp. Med."},{"key":"785_CR277","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1084\/jem.20032220","volume":"199","author":"LC Bonifaz","year":"2004","unstructured":"Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815\u2013824 (2004).","journal-title":"J. Exp. Med."},{"key":"785_CR278","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1172\/JCI34584","volume":"118","author":"D Sancho","year":"2008","unstructured":"Sancho, D. et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118, 2098\u20132110 (2008).","journal-title":"J. Clin. Invest."},{"key":"785_CR279","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.7150\/ijbs.57038","volume":"17","author":"MO Silva","year":"2021","unstructured":"Silva, M. O. et al. Antigen delivery to DEC205+ dendritic cells induces immunological memory and protective therapeutic effects against HPV-associated tumors at different anatomical sites. Int. J. Biol. Sci. 17, 2944\u20132956 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"785_CR280","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1158\/0008-5472.CAN-05-0938","volume":"65","author":"K Mahnke","year":"2005","unstructured":"Mahnke, K. et al. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 65, 7007\u20137012 (2005).","journal-title":"Cancer Res."},{"key":"785_CR281","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4049\/jimmunol.1401903","volume":"194","author":"E Hartung","year":"2015","unstructured":"Hartung, E. et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J. Immunol. 194, 1069\u20131079 (2015).","journal-title":"J. Immunol."},{"key":"785_CR282","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-16-0128","volume":"4","author":"W Yin","year":"2016","unstructured":"Yin, W. et al. Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity. Cancer Immunol. Res. 4, 823\u2013834 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR283","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1158\/0008-5472.CAN-09-4480","volume":"70","author":"RK Sharma","year":"2010","unstructured":"Sharma, R. K. et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 70, 3945\u20133954 (2010).","journal-title":"Cancer Res."},{"key":"785_CR284","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fimmu.2019.00294","volume":"10","author":"NK Botelho","year":"2019","unstructured":"Botelho, N. K. et al. Combination of synthetic long peptides and XCL1 fusion proteins results in superior tumor control. Front. Immunol. 10, 294 (2019).","journal-title":"Front. Immunol."},{"key":"785_CR285","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/2326-6066.CIR-19-0210","volume":"8","author":"K Chen","year":"2020","unstructured":"Chen, K. et al. XCL1\/Glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti-PD-1 efficacy. Cancer Immunol. Res. 8, 81\u201393 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR286","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004309","volume":"10","author":"C Le Gall","year":"2022","unstructured":"Le Gall, C. et al. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion. J. Immunother. Cancer 10, e004309 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR287","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","volume":"10","author":"ST Ferris","year":"2022","unstructured":"Ferris, S. T. et al. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol. Res. 10, 920\u2013931 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR288","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000474","volume":"8","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells. J. Immunother. Cancer 8, e000474 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR289","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1158\/1078-0432.CCR-23-3477","volume":"30","author":"S Saito","year":"2024","unstructured":"Saito, S. et al. Targeting dendritic cell dysfunction to circumvent anti-PD1 resistance in head and neck cancer. Clin. Cancer Res. 30, 1934\u20131944 (2024).","journal-title":"Clin. Cancer Res."},{"key":"785_CR290","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood.V99.5.1676","volume":"99","author":"M Merad","year":"2002","unstructured":"Merad, M., Sugie, T., Engleman, E. G. & Fong, L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99, 1676\u20131682 (2002).","journal-title":"Blood"},{"key":"785_CR291","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005141","volume":"10","author":"JK Schwarze","year":"2022","unstructured":"Schwarze, J. K. et al. Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. J. Immunother. Cancer 10, e005141 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR292","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT04571632 (2022)."},{"key":"785_CR293","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05773859 (2024)."},{"key":"785_CR294","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.410","volume":"2","author":"AM Swartz","year":"2022","unstructured":"Swartz, A. M. & Nair, S. K. The in vitro differentiation of human CD141+ CLEC9A+ dendritic cells from mobilized peripheral blood CD34+ hematopoietic stem cells. Curr. Protoc. 2, e410 (2022).","journal-title":"Curr. Protoc."},{"key":"785_CR295","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1007\/s00262-021-02899-3","volume":"70","author":"J van Eck van der Sluijs","year":"2021","unstructured":"van Eck van der Sluijs, J. et al. Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunol. Immunother. 70, 3167\u20133181 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR296","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1016\/j.celrep.2018.05.068","volume":"23","author":"ME Kirkling","year":"2018","unstructured":"Kirkling, M. E. et al. Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells. Cell Rep. 23, 3658\u20133672.e3656 (2018).","journal-title":"Cell Rep."},{"key":"785_CR297","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","volume":"37","author":"MK Ruhland","year":"2020","unstructured":"Ruhland, M. K. et al. Visualizing synaptic transfer of tumor antigens among dendritic cells. Cancer Cell 37, 786\u2013799.e785 (2020).","journal-title":"Cancer Cell"},{"key":"785_CR298","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd.2018.132","volume":"17","author":"F Pastor","year":"2018","unstructured":"Pastor, F. et al. An RNA toolbox for cancer immunotherapy. Nat. Rev. Drug. Discov. 17, 751\u2013767 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"785_CR299","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","volume":"4","author":"S Van Lint","year":"2016","unstructured":"Van Lint, S. et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol. Res. 4, 146\u2013156 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR300","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof, S. et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann. Oncol. 24, 2686\u20132693 (2013).","journal-title":"Ann. Oncol."},{"key":"785_CR301","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","volume":"34","author":"S Wilgenhof","year":"2016","unstructured":"Wilgenhof, S. et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 34, 1330\u20131338 (2016).","journal-title":"J. Clin. Oncol."},{"key":"785_CR302","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","volume":"69","author":"Y Jansen","year":"2020","unstructured":"Jansen, Y. et al. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol. Immunother. 69, 2589\u20132598 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR303","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"785_CR304","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"785_CR305","doi-asserted-by":"publisher","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03334-7 (2025).","DOI":"10.1038\/s41591-024-03334-7"},{"key":"785_CR306","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"785_CR307","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/2159-8290.CD-24-1196","volume":"14","author":"P Berraondo","year":"2024","unstructured":"Berraondo, P., Cuesta, R., Sanmamed, M. F. & Melero, I. Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines. Cancer Discov. 14, 2021\u20132024 (2024).","journal-title":"Cancer Discov."},{"key":"785_CR308","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.celrep.2013.04.007","volume":"3","author":"J Schonheit","year":"2013","unstructured":"Schonheit, J. et al. PU.1 level-directed chromatin structure remodeling at the Irf8 gene drives dendritic cell commitment. Cell Rep. 3, 1617\u20131628 (2013).","journal-title":"Cell Rep."},{"key":"785_CR309","doi-asserted-by":"publisher","first-page":"E998","DOI":"10.1073\/pnas.1319228111","volume":"111","author":"GC Ippolito","year":"2014","unstructured":"Ippolito, G. C. et al. Dendritic cell fate is determined by BCL11A. Proc. Natl Acad. Sci. USA 111, E998\u2013E1006 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR310","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20120030","volume":"209","author":"AT Satpathy","year":"2012","unstructured":"Satpathy, A. T. et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J. Exp. Med. 209, 1135\u20131152 (2012).","journal-title":"J. Exp. Med."},{"key":"785_CR311","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1084\/jem.20172323","volume":"215","author":"CM Lau","year":"2018","unstructured":"Lau, C. M. et al. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells. J. Exp. Med. 215, 2265\u20132278 (2018).","journal-title":"J. Exp. Med."},{"key":"785_CR312","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.celrep.2018.07.033","volume":"24","author":"S Balan","year":"2018","unstructured":"Balan, S. et al. Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity. Cell Rep. 24, 1902\u20131915.e1906 (2018).","journal-title":"Cell Rep."},{"key":"785_CR313","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.immuni.2018.11.010","volume":"50","author":"M Chopin","year":"2019","unstructured":"Chopin, M. et al. Transcription factor PU.1 promotes conventional dendritic cell identity and function via induction of transcriptional regulator DC-SCRIPT. Immunity 50, 77\u201390 e75 (2019).","journal-title":"Immunity"},{"key":"785_CR314","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-022-04866-z","volume":"607","author":"TT Liu","year":"2022","unstructured":"Liu, T. T. et al. Ablation of cDC2 development by triple mutations within the Zeb2 enhancer. Nature 607, 142\u2013148 (2022).","journal-title":"Nature"},{"key":"785_CR315","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imr.13281","volume":"321","author":"C Luri-Rey","year":"2024","unstructured":"Luri-Rey, C. et al. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming. Immunol. Rev. 321, 143\u2013151 (2024).","journal-title":"Immunol. Rev."},{"key":"785_CR316","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28, 578\u2013590 (2009).","journal-title":"EMBO J."},{"key":"785_CR317","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1524","volume":"2","author":"S Pawaria","year":"2011","unstructured":"Pawaria, S. & Binder, R. J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2, 521 (2011).","journal-title":"Nat. Commun."},{"key":"785_CR318","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/j.1398-9995.2010.02426.x","volume":"65","author":"T Muller","year":"2010","unstructured":"Muller, T. et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 65, 1545\u20131553 (2010).","journal-title":"Allergy"},{"key":"785_CR319","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"785_CR320","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1126\/science.aad0779","volume":"350","author":"E Vacchelli","year":"2015","unstructured":"Vacchelli, E. et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350, 972\u2013978 (2015).","journal-title":"Science"},{"key":"785_CR321","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med."},{"key":"785_CR322","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192282","volume":"217","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J. Exp. Med. 217, e20192282 (2020).","journal-title":"J. Exp. Med."},{"key":"785_CR323","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084\u20131089 (2015).","journal-title":"Science"},{"key":"785_CR324","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"785_CR325","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94952","volume":"3","author":"M Uribe-Herranz","year":"2018","unstructured":"Uribe-Herranz, M. et al. Gut microbiota modulates adoptive cell therapy via CD8alpha dendritic cells and IL-12. JCI Insight 3, e94952 (2018).","journal-title":"JCI Insight"},{"key":"785_CR326","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600\u2013605 (2019).","journal-title":"Nature"},{"key":"785_CR327","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jcmgh.2021.06.001","volume":"12","author":"JA Owens","year":"2021","unstructured":"Owens, J. A. et al. Lactobacillus rhamnosus GG orchestrates an antitumor immune response. Cell Mol. Gastroenterol. Hepatol. 12, 1311\u20131327 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"785_CR328","doi-asserted-by":"publisher","first-page":"1868122","DOI":"10.1080\/2162402X.2020.1868122","volume":"10","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12. Oncoimmunology 10, 1868122 (2021).","journal-title":"Oncoimmunology"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00785-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:15:11Z","timestamp":1743221711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00785-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":328,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1038\/s41568-024-00785-5","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"3 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M. acknowledges grants from Roche, Alligator, Genmab, BMS, AstraZeneca, Pharmamar and Highlight Therapeutics, as well as consultancy fees from BMS, Roche, Genmab, Numab, F-Star, Pierre Fabre, Sanofi, Alligator, AstraZeneca, Curon, Pioneers, Bright Peaks and Pharmamar. M.E.R.-R. reports receiving research funding from Roche and Highlight Therapeutics and speaker\u2019s bureau honoraria from BMS and ROCHE.\u00a0The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}